FIGURE 3.

Split‐luciferase complementation assay reveals FLPK as inhibitor of the FGF14:Nav1.6 complex. HEK293 cells were transiently transfected with CD4‐Nav1.6‐NLuc and CLuc‐FGF14 (a,f), CLuc‐FGF14^V160A (b), or CLuc‐FGF14^Y158A (c), CLuc‐FGF14^Y158A/V160A (d), or CLuc‐FGF14^Y158N/V160N (e) and treated with peptides (FLPK, PLEV, or EYYV) or 0.5% DMSO alone (vehicle) in 96‐well plates. (a‐e), bar graphs representing percent maximal luminescence response (normalized to DMSO controls) from transfected HEK293 cells treated with peptides (50 µM) or 0.5% DMSO alone. (f) dose‐response for FLPK (1, 10, 25, 50, 75, 100, 150, and 250 µM) against CLuc‐FGF14:CD4‐Nav1.6‐NLuc. The data were analyzed using one‐way ANOVA with post hoc Dunnett's analysis (n = 6–10 independent experiments; n = 4 replicates). Data are mean ± SEM. SEMs are shown as error bars in the figures. *p < .05, **p < .01, ***p < .001; NS = nonsignificant. Student's t test